Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.

about

Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.

Item

http://www.wikidata.org/entity/Q40616446

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Secondary Metastases Resection ...... g: Results of the ETNA Cohort.

@en

type

Item

label

Secondary Metastases Resection ...... g: Results of the ETNA Cohort.

@en

prefLabel

Secondary Metastases Resection ...... g: Results of the ETNA Cohort.

@en

P1476

Secondary Metastases Resection ...... g: Results of the ETNA Cohort.

@en

P2093

Annie Fourrier-Réglat

http://www.w3.org/2001/XMLSchema#string

Aurélie Balestra

http://www.w3.org/2001/XMLSchema#string

Christophe Laurent

http://www.w3.org/2001/XMLSchema#string

Denis Smith

http://www.w3.org/2001/XMLSchema#string

ETNA study group

http://www.w3.org/2001/XMLSchema#string

Jérémy Jové

http://www.w3.org/2001/XMLSchema#string

Magali Rouyer

http://www.w3.org/2001/XMLSchema#string

Philip Robinson

http://www.w3.org/2001/XMLSchema#string

Pierre Michel

http://www.w3.org/2001/XMLSchema#string

Rosine Guimbaud

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.

Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy

P2888

s11523-015-0377-6

P304

83-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-015-0377-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicole Tubiana Mathieu

Alain Ravaud

Nicholas Moore

Pernelle Noize

P577

2015-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26298481

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

bevacizumab